8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)

10-Q - Third Harmonic Bio, Inc. (0001923840) (Filer)

144 - Third Harmonic Bio, Inc. (0001923840) (Subject)

144 - Third Harmonic Bio, Inc. (0001923840) (Subject)

8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)

10-Q - Third Harmonic Bio, Inc. (0001923840) (Filer)

8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)

8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)

10-Q - Third Harmonic Bio, Inc. (0001923840) (Filer)

ARS - Third Harmonic Bio, Inc. (0001923840) (Filer)

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m. A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event. About Third Harmonic Bio, Inc.Third Harmonic Bio is a clinical

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences: Natalie Holles, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 3:00 p.m. ESTChris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:00 a.m. GMT / 6:00 a.m. E

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. "As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress i

SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences: Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ETTD Cowen Virtual Chronic Urticaria Summit on Friday, September 20, 2024, at 3:00 p.m. ET A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archiv

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences: Morgan Stanley 22nd Healthcare Conference on Wednesday, September 4, 2024, at 9:15 a.m. ETStifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ET A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An

THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the second quarter June 30, 2024, along with business updates. "We are making excellent progress in our Phase 1 SAD/MAD clinical trial of THB335 and

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET. A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event. About Third Harmonic Bio, Inc.Third Harmonic Bio is a clinical stage biopharma

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H'25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D., to Chief Scientific Officer, Dennis Dean, Ph.D., to Chief Non-Clinical Development Officer, and the promotion of Jennifer Dittman to Chief Development Operations Officer Strong financial position with cash and cash equivalents totaling $262.8 million as of March 31, 2024 SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical stage biopharmaceutical company focused on advancing the next wav

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. "Our team's execution continues to be outstanding, with the filing of our U.S. IND for THB335 ahead of our internal timelines for submission," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "We look forw

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ

Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business de